Monte Rosa Therapeutics (GLUE) Cash from Operations (2020 - 2026)
Monte Rosa Therapeutics (GLUE) posted quarterly Cash from Operations of 37369000.0 for Q1 2026, up 17.86% year-over-year from 31707368.24 in Q1 2025, and up 13.12% quarter-over-quarter from 43014000.0 in Q4 2025.
Powered by 
Analysis
Monte Rosa Therapeutics (GLUE) Cash from Operations (2020 - 2026) Analysis & Trends
Monte Rosa Therapeutics' Cash from Operations history runs 7 years deep, the most recent figure standing at 37369000.0 for Q1 2026.
- In Q1 2026, Cash from Operations rose 17.86% year-over-year to 37369000.0; the TTM figure through Mar 2026 stood at 14675000.0 (down 142.33% YoY), while the FY2025 annual figure was 22798000.0, down 154.29% from the prior year.
- Cash from Operations for Q1 2026 stood at 37369000.0, up from 43014000.0 in the prior quarter.
- The five-year high for Cash from Operations was 128922000.0 in Q4 2024, with the low at 45492000.0 in Q1 2025.
- The 5-year median for Cash from Operations is 24706000.0 (2023), against an average of 9084647.06.
- Peak annual rise in Cash from Operations reached 578.37% in 2025, while the deepest fall reached 133.36% in 2025.
- Monte Rosa Therapeutics' Cash from Operations stood at 23961000.0 in 2022, then surged by 223.68% to 29634000.0 in 2023, then soared by 335.05% to 128922000.0 in 2024, then plunged by 133.36% to 43014000.0 in 2025, then gained by 13.12% to 37369000.0 in 2026.
- Business Quant data shows GLUE's Cash from Operations at 37369000.0 in Q1 2026, 43014000.0 in Q4 2025, and 100428000.0 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -526.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -387.32 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 462.82 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 326.72 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 728.46 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -88.83 Mn |
| 10 | Monte Rosa Therapeutics | 1.40 Bn | 771.57 Mn | - | -44.11 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -44.11 Mn |
| Mar 31, 2026 | -37.37 Mn |
| Dec 31, 2025 | -43.01 Mn |
| Sep 30, 2025 | 100.43 Mn |
| Jun 30, 2025 | -34.72 Mn |
| Mar 31, 2025 | -45.49 Mn |
| Dec 31, 2024 | 128.92 Mn |
| Sep 30, 2024 | -20.99 Mn |
| Jun 30, 2024 | -27.77 Mn |
| Mar 31, 2024 | -38.17 Mn |
| Dec 31, 2023 | 29.63 Mn |
| Sep 30, 2023 | -24.71 Mn |
| Jun 30, 2023 | -25.32 Mn |
| Mar 31, 2023 | -23.41 Mn |
| Dec 31, 2022 | -23.96 Mn |
| Sep 30, 2022 | -20.60 Mn |
| Jun 30, 2022 | -20.50 Mn |
| Mar 31, 2022 | -27.40 Mn |
| Dec 31, 2021 | -14.17 Mn |
| Sep 30, 2021 | -17.79 Mn |